Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares

Rhea-AI Filing Summary

WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.

Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WEISS MICHAEL S

Role Executive Vice Chairman

Type	Security	Shares	Price	Value
Grant/Award	common stock, par value $0.001	475,424	$0.00	--

Holdings After Transaction: common stock, par value $0.001 — 2,276,562 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEISS MICHAEL S

(Last) (First) (Middle)

C/O FORTRESS BIOTECH, INC.

1111 KANE CONCOURSE SUITE 301

(Street)

BAY HARBOR ISLANDS FLORIDA 33154

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [ FBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
common stock, par value $0.001	03/18/2026		A		475,424(1)	A	$0	2,276,562	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.

	/s/ Samuel Berry, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fortress Biotech (FBIO) report for Michael S. Weiss?

Fortress Biotech reported that Executive Vice Chairman Michael S. Weiss received 475,424 restricted shares of common stock as an equity grant. The award was made on March 18, 2026 under the company’s Long-Term Incentive Plan, increasing his directly held share count.

Was the Fortress Biotech (FBIO) insider transaction a market buy or sell?

The transaction was not a market buy or sell. Michael S. Weiss received 475,424 restricted shares as a grant with a reported price of $0.00 per share, indicating a compensation-related award rather than an open-market purchase or sale of Fortress Biotech stock.

How many Fortress Biotech (FBIO) shares does Michael S. Weiss hold after this grant?

After receiving the 475,424 restricted shares, Michael S. Weiss directly holds 2,276,562 shares of Fortress Biotech common stock. This total includes the newly awarded shares granted on March 18, 2026 under the company’s Long-Term Incentive Plan, as reported in the Form 4 filing.

What plan governed the recent Fortress Biotech (FBIO) share grant to Michael S. Weiss?

The grant of 475,424 restricted shares to Michael S. Weiss was made under Fortress Biotech’s Long-Term Incentive Plan. The footnote explains that these restricted shares were awarded on March 18, 2026 pursuant to that plan as part of his equity-based compensation package.

What does transaction code “A” mean in the Fortress Biotech (FBIO) Form 4?

In this Form 4, transaction code “A” indicates a grant, award, or other acquisition of shares. For Fortress Biotech, it reflects that Michael S. Weiss acquired 475,424 restricted common shares as an equity award, not through an open-market trade or option exercise.